Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Patients received 5-azacytidine (AZA) 75 mg/m(2) intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at ∼1-month intervals. Forty-three acute myeloid leukemia (AML) patients with a median age of 64 years (range, 24-87 years) were enrolled; 37 wer...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ravandi, Farhad, Alattar, Mona Lisa, Grunwald, Michael R., Rudek, Michelle A., Rajkhowa, Trivikram, Richie, Mary Ann, Pierce, Sherry, Daver, Naval, Garcia-Manero, Guillermo, Faderl, Stefan, Nazha, Aziz, Konopleva, Marina, Borthakur, Gautam, Burger, Jan, Kadia, Tapan, Dellasala, Sara, Andreeff, Michael, Cortes, Jorge, Kantarjian, Hagop, Levis, Mark
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2013
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674666/
https://ncbi.nlm.nih.gov/pubmed/23613521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-480228
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים